Physician profile
Faiza Bhatti
NPI 1144556499
$37,820.03
in general payments reported to CMS, 2019-2025
21 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.29 · 2020: $41.46 · 2021: $8,101 · 2022: $12K · 2023: $13K · 2024: $3,141 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,785 · Travel and Lodging: $2,778 · Consulting Fee: $600 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,667.00 |
| Food and Beverage | $2,784.96 |
| Travel and Lodging | $2,778.34 |
| Consulting Fee | $600.00 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30,500.24 | 2021-2024 | Zeposia |
| Pfizer INC. | $3,767.23 | 2021-2025 | |
| Abbvie INC. | $1,051.69 | 2020-2025 | Rinvoq, Skyrizi, Linzess |
| Celgene Corporation | $715.28 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $488.95 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $272.52 | 2023-2025 | Tremfya, Stelara |
| Genzyme Corporation | $247.55 | 2022-2025 | |
| Lilly USA, LLC | $208.84 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $171.29 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $112.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.39 | 2022-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $56.67 | 2024-2025 | Vowst |
| Olympus America INC. | $28.91 | 2021-2022 | |
| Novo Nordisk INC | $22.44 | 2022 | |
| Redhill Biopharma INC. | $21.39 | 2023 | Aemcolo, Talicia, Movantik |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $20.19 | 2023 | Renflexis, Hadlima |
| Ambu INC. | $19.74 | 2024 | |
| Capsovision, INC. | $16.87 | 2024 | Capsocam Plus |
| Amgen INC. | $15.91 | 2022 | |
| Sandoz INC. | $14.99 | 2024 | Hyrimoz |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiza Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.